Delfi Diagnostics Fragmentomics Lung Cancer Test Nears Key Milestone For FDA Path, Reimbursement

 
• By Marion Webb
  
Pending trial results, Delfi Diagnostics plans to file for FDA clearance of its lung cancer screening blood test, which received breakthrough device designation in 2021. (Delfi Diagnostics )

More from Clinical Trials

More from R&D